P/ 310-827-7707 | F/ 310-574-4002 | MAIL@PROSTATEONCOLOGY.COM
BY MARK SCHOLZ, MD A number of interventions are available that can substantially reduce adverse side effects from testosterone inactivating pharmaceuticals (TIP). Side effects vary from patient to patient and are influenced by the …
BY MARK SCHOLZ, MD New prostate cancer drugs come to market quite rarely because the studies mandated by the FDA cost hundreds of millions of dollars. The FDA requires these studies to randomly allocate men into …
BY MARK SCHOLZ, MD It is generally understood that diabetes is a disease of insulin deficiency. Until now, it has not been widely recognized that insulin is high-octane fuel for …
BY MARK SCHOLZ, MD Google keeps track of what is searched most frequently. Since prostate cancer is common, it’s hardly surprising that people who research aches or pains “down there” …